BeyondSpring Inc. Ordinary Shares (BYSI)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 44
- Market Cap
- $30M
About BeyondSpring Inc. Ordinary Shares
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.
SentiSense also tracks daily options readings for BeyondSpring Inc. Ordinary Shares: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
BeyondSpring Inc. Ordinary Shares stock analysis, sentiment tracking, and market intelligence on SentiSense.